14-day Premium Trial Subscription Sign Up For FreeGet Free

Stock Market Week 20 - The Game Is On! Click to watch.

CytomX Therapeutics Stock Forecast

NASDAQ:CTMX BUY SELL

$1.73 (-1.70%)

Volume: 662.3k

Closed: May 16, 2022

Hollow Logo Score: -2.073

CytomX Therapeutics Stock Forecast

BUY SELL NASDAQ:CTMX
$1.73 (-1.70%)

Volume: 662.3k

Closed: May 16, 2022

Score Hollow Logo -2.073

CytomX Therapeutics Stock Forecast NASDAQ:CTMX

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-03-02 420.23% JP Morgan $10.00 $9.00 Maintains Overweight
2022-01-18 304.62% Barclays $7.00 Upgrades Underweight Overweight
2021-12-22 535.84% HC Wainwright & Co. $12.00 $11.00 Maintains Buy
2021-11-15 824.86% BTIG $16.00 Initiates Coverage On Buy
2021-05-28 304.62% Barclays $9.00 $7.00 Downgrades Equal-Weight Underweight
2021-03-29 709.25% JP Morgan $14.00 Initiates Coverage On Overweight
2021-03-23 - Jefferies - Upgrades Hold Buy
2020-09-22 - Guggenheim - Downgrades Buy Neutral
2020-06-01 478.03% Jefferies $16.00 $10.00 Downgrades Buy Hold
2020-05-14 593.64% HC Wainwright & Co. $16.00 $12.00 Maintains Buy
2020-05-08 824.86% HC Wainwright & Co. $14.00 $16.00 Reiterates Buy
2020-03-24 - Wedbush - Upgrades Neutral Outperform
2020-02-28 767.05% Nomura $22.00 $15.00 Maintains Buy
2019-11-20 824.86% Guggenheim $16.00 Initiates Coverage On Buy
2019-11-11 362.43% Wedbush $25.00 $8.00 Downgrades Outperform Neutral
2019-06-13 824.86% Mizuho $16.00 Initiates Coverage On Buy
2019-06-03 1229.48% Cantor Fitzgerald $21.00 $23.00 Reiterates Overweight
2019-05-14 - Cantor Fitzgerald - Initiates Coverage On Overweight

CTMX Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -59.79% during the next 3 months and, with a 90% probability hold a price between $0.52 and $0.74 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2022-05-18 $1.26 $1.53 $1.80
2022-05-19 $1.21 $1.48 $1.76
2022-05-20 $1.16 $1.44 $1.71
2022-05-23 $1.12 $1.39 $1.66
2022-05-24 $1.07 $1.35 $1.62
2022-05-25 $1.03 $1.30 $1.57
2022-05-26 $0.98 $1.25 $1.53
2022-05-27 $0.93 $1.21 $1.48
2022-05-31 $0.89 $1.16 $1.44
2022-06-01 $0.84 $1.12 $1.39
2022-06-02 $0.80 $1.07 $1.34
2022-06-03 $0.75 $1.02 $1.30
2022-06-06 $0.71 $0.98 $1.25
2022-06-07 $0.66 $0.93 $1.21
2022-06-08 $0.61 $0.89 $1.16
2022-06-09 $0.57 $0.84 $1.11
2022-06-10 $0.52 $0.80 $1.07
2022-06-13 $0.48 $0.75 $1.02
2022-06-14 $0.43 $0.70 $0.98
2022-06-15 $0.39 $0.66 $0.93
2022-06-16 $0.34 $0.61 $0.89
2022-06-17 $0.29 $0.57 $0.84
2022-06-21 $0.25 $0.52 $0.79
2022-06-22 $0.20 $0.48 $0.75
2022-06-23 $0.16 $0.43 $0.70
2022-06-24 $0.11 $0.38 $0.66
2022-06-27 $0.0646 $0.34 $0.61
2022-06-28 $0.0188 $0.29 $0.57
2022-06-29 $-0.0270 $0.25 $0.52
2022-06-30 $-0.0728 $0.20 $0.47

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition, it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., ImmunoGen, Inc., and Th... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 108 000+ Happy Subscribers

Don't miss out on the runners!

Sign for StockInvest.us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT